Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy
- PMID: 17805556
- DOI: 10.1007/s00417-007-0667-5
Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy
Abstract
Purpose: To evaluate the effect of posterior juxtascleral triamcinolone acetonide (TA) injection combined with photodynamic therapy with verteporfin (PDT) for treating exudative age-related macular degeneration (AMD), the best-corrected visual acuity (BCVA), the retreatment rates and the rate of choroidal hypoperfusion were investigated.
Methods: A total of 67 eyes with subfoveal choroidal neovascularization (CNV) due to AMD were included. Forty-four eyes underwent PDT alone (PDT-alone group), and 23 eyes underwent PDT with the posterior juxtascleral injection of TA (PDT+TA group). Every 3 months after the PDT, the eyes were evaluated with regard to BCVA and requirement for retreatment by fluorescein angiography (FA) with the aid of optical coherence tomography (OCT). Choroiocapillaris hypoperfusion was assessed by indocyanine green angiography (ICGA) at 3 and 12 months. All patients completed a 1-year follow-up.
Results: At the baseline, there was no difference in lesion type, size or visual acuity between the two groups. At 1 year, the change in BCVA was -0.0811 logarithm of the minimum angle of resolution (LogMAR) in the PDT-alone group, compared with -0.0432 logMAR in the PDT+TA group. There was no significant difference in the change in BCVA between the two groups (P = 0.6910). The PDT+TA group required a lower mean number of treatments (1.64 compared with 2.34 [P = 0.0223]) and showed a higher rate of choriocapillaris occlusion at 3 months, but no significant difference at 1 year (P = 0.9243)
Conclusions: Fewer retreatments were required in the TA+PDT group. There was no significant difference in the change in BCVA between the two groups. Adjacent TA may promote short-term choriocapillaris hypoperfusion.
Similar articles
-
Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin.Ophthalmology. 2005 Nov;112(11):1896-903. doi: 10.1016/j.ophtha.2005.06.018. Epub 2005 Oct 7. Ophthalmology. 2005. PMID: 16214216
-
Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.Retina. 2010 Mar;30(3):495-502. doi: 10.1097/IAE.0b013e3181bcedbe. Retina. 2010. PMID: 19996828
-
Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.Ophthalmology. 2006 Dec;113(12):2243-50. doi: 10.1016/j.ophtha.2006.04.039. Epub 2006 Sep 25. Ophthalmology. 2006. PMID: 16996600 Clinical Trial.
-
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.Curr Drug Targets. 2011 Feb;12(2):149-72. doi: 10.2174/138945011794182746. Curr Drug Targets. 2011. PMID: 20887246 Review.
-
Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration.Eur J Ophthalmol. 2006 Nov-Dec;16(6):824-34. doi: 10.1177/112067210601600607. Eur J Ophthalmol. 2006. PMID: 17191188 Review.
Cited by
-
Nerve fiber layer thickness in exudative age-related macular degeneration in Japanese patients.Graefes Arch Clin Exp Ophthalmol. 2010 Mar;248(3):353-9. doi: 10.1007/s00417-009-1222-3. Epub 2009 Oct 31. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 19882162
-
Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-1alpha with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system.Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1413-22. doi: 10.1007/s00417-008-0858-8. Epub 2008 Jun 4. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 18523795
-
One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.Jpn J Ophthalmol. 2012 Nov;56(6):599-607. doi: 10.1007/s10384-012-0183-y. Epub 2012 Sep 19. Jpn J Ophthalmol. 2012. PMID: 22990616
-
Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.Pharmaceutics. 2020 Mar 16;12(3):269. doi: 10.3390/pharmaceutics12030269. Pharmaceutics. 2020. PMID: 32188045 Free PMC article. Review.
-
Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial.J Ophthalmic Vis Res. 2014 Oct-Dec;9(4):469-77. doi: 10.4103/2008-322X.150826. J Ophthalmic Vis Res. 2014. PMID: 25709773 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical